GlassScriptPhysician profile
Timothy Ellis Crouch
NPI 1699832022
$3,048.65
in general payments reported to CMS, 2019-2025
21 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $508 · 2021: $376 · 2022: $459 · 2023: $549 · 2024: $398 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.26 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $571.55 | 2020-2025 | Andembry, Haegarda |
| Genzyme Corporation | $546.39 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $280.57 | 2019-2024 | Dupixent |
| Pfizer INC. | $242.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $215.53 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $180.00 | 2019-2023 | |
| Pharming Healthcare, INC. | $143.64 | 2019-2025 | Ruconest |
| Grifols USA, LLC | $141.68 | 2019-2025 | Xembify |
| Astrazeneca Pharmaceuticals LP | $135.31 | 2019-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $111.21 | 2020-2025 | Cuvitru, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.10 | 2019-2021 | |
| Optinose US, INC. | $83.51 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $54.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.73 | 2021 | |
| Paratek Pharmaceuticals, INC. | $41.32 | 2025 | Xhance, Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $39.20 | 2021 | |
| Amgen INC. | $34.00 | 2025 | |
| Genentech USA, INC. | $32.67 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.01 | 2019-2023 | |
| Biocryst Pharmaceuticals, INC. | $17.84 | 2020 | |
| Aimmune Therapeutics, INC. | $17.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Crouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.